156 related articles for article (PubMed ID: 16182537)
1. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities.
Moon MJ; Lee SK; Lee JW; Song WK; Kim SW; Kim JI; Cho C; Choi SJ; Kim YC
Bioorg Med Chem; 2006 Jan; 14(1):237-46. PubMed ID: 16182537
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro.
Kim SH; Choi SJ; Kim YC; Kuh HJ
Arch Pharm Res; 2009 Jun; 32(6):915-22. PubMed ID: 19557370
[TBL] [Abstract][Full Text] [Related]
3. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
Zhen Y; Sørensen V; Jin Y; Suo Z; Wiedłocha A
Oncogene; 2007 Sep; 26(44):6372-85. PubMed ID: 17533378
[TBL] [Abstract][Full Text] [Related]
4. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.
Hoessel R; Leclerc S; Endicott JA; Nobel ME; Lawrie A; Tunnah P; Leost M; Damiens E; Marie D; Marko D; Niederberger E; Tang W; Eisenbrand G; Meijer L
Nat Cell Biol; 1999 May; 1(1):60-7. PubMed ID: 10559866
[TBL] [Abstract][Full Text] [Related]
5. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.
Damiens E; Baratte B; Marie D; Eisenbrand G; Meijer L
Oncogene; 2001 Jun; 20(29):3786-97. PubMed ID: 11439342
[TBL] [Abstract][Full Text] [Related]
6. 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.
Choi SJ; Lee JE; Jeong SY; Im I; Lee SD; Lee EJ; Lee SK; Kwon SM; Ahn SG; Yoon JH; Han SY; Kim JI; Kim YC
J Med Chem; 2010 May; 53(9):3696-706. PubMed ID: 20361800
[TBL] [Abstract][Full Text] [Related]
7. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
10. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
[TBL] [Abstract][Full Text] [Related]
13. Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.
Perabo FG; Frössler C; Landwehrs G; Schmidt DH; von Rücker A; Wirger A; Müller SC
Anticancer Res; 2006; 26(3A):2129-35. PubMed ID: 16827155
[TBL] [Abstract][Full Text] [Related]
14. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells.
Lee JW; Moon MJ; Min HY; Chung HJ; Park EJ; Park HJ; Hong JY; Kim YC; Lee SK
Bioorg Med Chem Lett; 2005 Sep; 15(17):3948-52. PubMed ID: 15993584
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives.
Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL
Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594
[TBL] [Abstract][Full Text] [Related]
20. Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells.
Choi SJ; Moon MJ; Lee SD; Choi SU; Han SY; Kim YC
Bioorg Med Chem Lett; 2010 Mar; 20(6):2033-7. PubMed ID: 20153646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
